Monument Therapeutics secures £850k to advance breakthrough schizophrenia treatment 25 February 2025 Manchester, 25th February 2025 — Monument Therapeutics, an innovative neuroscience company applying digital biomarkers to psychiatric drug development, has secured £850k in further funding led by ACF Investors, with participation from Wren Capital, o2h Ventures, and angel investors. The investment will be used […]

Cambridge Cognition submits FDA Letter of Intent for Cognitive Impairment Assessments in Schizophrenia 18 February 2025 Cambridge Cognition (AIM: COG), the brain health software group specialising in digital products to advance clinical research and patient treatment, has submitted a Letter of Intent to the U.S. Food and Drug Administration (FDA) under the Drug Development Tool

Cambridge Cognition Launches In-House Rater Training Digital Measures that Matter Cambridge Cognition is excited to announce a new service that will help transform the quality and efficiency of brain health research. Our new Rater Training service combines with our existing digital tools to create a more streamlined and accurate way to conduct clinical studies focused

Actinogen Enhances Phase 2b/3 Alzheimer’s Trial with Our Full Digital Suite Digital Measures that Matter Cambridge Cognition is excited to announce the expansion of its partnership with Actinogen Medical Limited for the Phase 2b/3 XanaMILA Alzheimer’s disease trial. Building on the successful integration of Cambridge Cognition’s full product suite including Cognitive Assessments (CANTAB), electronic Clinical

Cambridge Cognition Highlights Positive CANTAB® Results in research by Bristol Myers Squibb Digital Measures that Matter Cambridge Cognition congratulates Bristol Myers Squibb for its recent FDA approval of Cobenfy (KarXT™ or Xanomeline and Trospium) and the exciting results published recently in The American Journal of Psychiatry1 showcasing the use of CANTAB® in two Phase III